UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~December~~January 213, ~~2025~~2026

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-35331		45-2492228
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

~~6100~~4020 ~~Tower~~Aspen ~~Circle~~Grove Drive, Suite ~~1000~~900 Franklin, Tennessee (Address of Principal Executive Offices) 37067 (Zip Code)

(615) 861-6000

(Registrant’s Telephone Number, including Area Code)

~~Not~~6100 ~~Applicable~~Tower Circle, Suite 1000

Franklin, Tennessee 37067

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ACHC		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

To the extent applicable, the information set forth in Item 7.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On ~~December~~January 213, ~~2025~~2026, representatives of Acadia Healthcare Company, Inc. ~~issued~~(“Acadia” or the “Company”) will be participating in the 44th Annual J.P. Morgan Healthcare Conference. In connection with the conference, there will be a ~~press~~live ~~release~~webcast ~~providing~~of ~~updated~~the ~~guidance~~Company’s ~~for~~presentation available on the ~~year~~Company’s ~~ended~~website ~~December~~starting 31at 5:15 p.m. Pacific Time / 7:15 p.m. Central Time on Tuesday, ~~2025~~January 13, 2026. ~~The~~During ~~press~~the ~~release~~Company’s ispresentation, ~~furnished~~Company ~~herewith~~representatives aswill ~~Exhibit~~discuss 99information ~~hereto~~described ~~and~~on isthe ~~incorporated~~slides ~~herein~~furnished bywith ~~reference~~this Current Report on Form 8-K as Exhibit 99.

~~The~~In ~~information~~conjunction ~~furnished~~with ~~pursuant~~the toconference, ~~Item~~management ~~7.01 in this Current Report on Form 8-K~~ is ~~being~~reaffirming ~~furnished and shall not be deemed “filed” for purposes of Section 18 of~~ the ~~Securities~~Company’s ~~Exchange~~2025 ~~Act~~financial ofguidance ~~1934,~~provided ~~as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference~~ in ~~any~~its ~~filing~~November ~~under the Securities Act of 1933~~5, as2025 ~~amended,~~earnings ~~or the Exchange Act~~release, ~~except~~ as ~~shall~~updated ~~be expressly set forth~~ by ~~specific~~its ~~reference~~December in2, ~~such~~2025 ~~filing.~~press release:

●

Revenue in the range of $3.28 billion to $3.30 billion;

●

Adjusted EBITDA in the range of $601 million to $611 million; and

●

Adjusted earnings per share in the range of $1.94 to $2.04.

The live webcast of the Company’s presentation, and the slides to be discussed during the presentation, will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. Please go to the site at least 15 minutes prior to the webcast to download and install any necessary software. A replay of the presentation will also be available on the Company’s website for thirty days.

The information furnished pursuant to Item 2.02 and Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K and the exhibits furnished herewith contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including statements related to the Company’s strategy, growth and anticipated operating results. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this report. The Company does not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties, and the Company’s future results could differ significantly from those expressed or implied by its forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of facility expansions, acquisitions, joint ventures and de novo transactions; (ii) the Company’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by the Company from government and commercial payors, including because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (“OBBBA”) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of the Company’s common stock and result in substantial payments and incremental regulatory burdens; (v) changes in expectations resulting from actuarial and other reviews of the Company’s liability reserves and other aspects of its business; (vi) the risk that the Company may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vii) potential disruptions to the Company’s information technology systems or a cybersecurity incident; and (viii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent the Company from realizing the expected benefits of its business strategies. These factors and others are more fully described in the Company’s periodic reports and other filings with the Securities and Exchange Commission.

Description of Business

Unless the context otherwise requires, all references herein to “Acadia,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries. Acadia Healthcare Company, Inc. is a holding company whose direct and indirect subsidiaries own and operate acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the U.S. and Puerto Rico. The terms “facilities,” “centers,” “clinics” and “hospitals” refer to entities owned, operated or managed by subsidiaries of Acadia Healthcare Company, Inc. References herein to “employees” refer to employees of subsidiaries of Acadia Healthcare Company, Inc.

Item 9.01 Financial Statements and Exhibits.

(d) ~~Exhibits~~Exhibit

99 ~~Press~~Slide ~~Release~~Presentation, dated ~~December~~January 213, ~~2025~~2026

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 2, 2025	ACADIA HEALTHCARE COMPANY, INC.
Date: January 13, 2026	ACADIA HEALTHCARE COMPANY, INC.
	By:	/s/ Brian P. Farley
		Brian P. Farley
		Executive Vice President, Secretary and General Counsel

Filing Compare · Acadia Healthcare Company, Inc.